All In Biotech

NDA 212690 · Jazz

Xywav

Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate, Sodium Oxybate · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jul 21, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

59

17 Phase 3, 4 recruiting

FAERS reports

9,150

7,263 serious, 85 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE. • Central Nervous System Depression XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses [see Warnings and Precautions ( 5.1 , 5.4 )]. Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving central nervous system stimulants [see Clinical Studies ( 14.1 , 14.2 , 14.3 )]. • Abuse and Misuse The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. Because of the risks of CNS depression and...

What it is approved for

From the label in effect Jul 1, 2025.

XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). 1.1 Narcolepsy XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. 1.2 Idiopathic Hypersomnia XYWAV is indicated for the treatment of idiopathic hypersomnia (IH) in adults.

Mechanism: XYWAV is a CNS depressant. The exact mechanism of action of XYWAV in the treatment of narcolepsy and idiopathic hypersomnia is unknown. XYWAV is a mixture of calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate (gamma-hydroxybutyrate). Gamma-hydroxybutyrate (GHB) is an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of XYWAV are mediated through GABA B actions during sleep at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 12, 2021 Supplement 6 · Efficacy · priority review OrphanLetterLabelReview
  • Jul 21, 2020 Original approval · Type 2 - New Active Ingredient · priority review OrphanLabelLetterReview
1 products under this application
  • XYWAV · CALCIUM OXYBATE 0.234GM/ML; MAGNESIUM OXYBATE 0.096GM/ML; POTASSIUM OXYBATE 0.13GM/ML; SODIUM OXYBATE 0.04GM/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxybate" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product administration interrupted1,548
  • surgery1,272
  • nausea999
  • product dose omission issue878
  • anxiety699
  • intentional dose omission593
  • dizziness545
  • headache527
  • intentional product use issue515
  • somnolence492
  • vomiting479
  • feeling abnormal450

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20161
20173
20196
202011
2021714
20221,707
20232,062
20242,063
20251,392
20261,190

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xywav (Sodium,Calcium,Mag,Pot Oxybate)

2024 spending

$211M

Beneficiaries

1,471

12,311 claims

Per beneficiary

$143,114

$37.03 per unit

View as table
YearSpending
2020$3,372,216
2021$84,233,084
2022$125,581,134
2023$168,733,996
2024$210,520,764

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 127 on PubMed

Sponsor: Jazz Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.